10-Q: TuHURA Biosciences Q3 2025: Losses Mount, Funding Critical

TuHURA Biosciences, Inc. reported significantly increased net losses and a critical cash position for Q3 2025, raising substantial doubt about its ability to continue as a going concern, despite advancing its clinical pipeline and pursuing new financing.

Summary

• Net loss for the three months ended September 30, 2025, was $7.1 million, an increase from $5.6 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $23.3 million, compared to $15.7 million for the nine months ended September 30, 2024.
• Cash and cash equivalents stood at $2.7 million as of September 30, 2025, down from $12.7 million at December 31, 2024.
• The company incurred $22.1 million of negative cash flows from operations for the nine months ended September 30, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months.
• The acquisition of Kineta, Inc. was completed on June 30, 2025, adding TBS-2025 (a VISTA-inhibiting monoclonal antibody) and Delta Opioid Receptor technology to the pipeline.
• A Phase 3 registration trial for IFx-2.0 in advanced or metastatic Merkel cell carcinoma was initiated in June 2025, utilizing the FDA's accelerated approval pathway.
• A $1.5 million bridge loan was secured in October 2025, and a shelf registration statement for a $50 million At-The-Market (ATM) offering was filed in November 2025.

Sentiment

Score: 3

Explanation: While the company made strategic progress with the Kineta merger and advancing IFx-2.0 to Phase 3, the significant increase in net losses, substantial cash burn, and explicit 'going concern' warning indicate a precarious financial position. The reliance on future capital raises, which are not assured, adds considerable risk.

Positives

• Initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 in first-line treatment for patients with advanced or metastatic Merkel cell carcinoma, utilizing the FDA's accelerated approval pathway.
• Completed the acquisition of Kineta, Inc. on June 30, 2025, expanding the immuno-oncology pipeline with TBS-2025 (a novel VISTA-inhibiting monoclonal antibody) and Delta Opioid Receptor technology.
• Successfully completed initial tranches of a $12.6 million private placement, receiving $8.9 million by June 30, 2025, following key milestones including FDA clinical hold lift and Phase 3 trial initiation.
• Secured a $1.5 million initial advance from a bridge loan transaction in October 2025 for working capital purposes, with potential for an additional $1.5 million.
• Filed a shelf registration statement for an At-The-Market (ATM) offering program to sell up to $50 million of common stock, providing a potential future funding mechanism.
• Recognized $713,508 in grant income for the nine months ended September 30, 2025, from a Business Innovation Research grant.

Negatives

• Net loss significantly increased to $7.1 million for Q3 2025 from $5.6 million for Q3 2024, and to $23.3 million for the nine months ended September 30, 2025, from $15.7 million for the prior year period.
• Cash and cash equivalents decreased substantially to $2.7 million as of September 30, 2025, from $12.7 million at December 31, 2024.
• Negative cash flows from operations more than doubled, reaching $22.1 million for the nine months ended September 30, 2025, compared to $12.1 million in the prior year.
• Management explicitly stated "substantial doubt about the Company's ability to continue as a going concern for the next 12 months."
• Operating expenses increased significantly, with research and development expenses up $5.1 million and general and administrative expenses up $6.5 million for the nine months ended September 30, 2025, compared to the prior year.
• A loss of $315,660 was recorded due to the change in fair value of Kineta merger holdback shares, reflecting an increase in the company's share price relative to the merger date.
• An aggregate of $0.5 million from the June 2025 private placement remains outstanding and is required to be purchased by December 31, 2025.

Risks

• Inability to fund planned operations for the next twelve months and continue as a going concern.
• Uncertainty in obtaining, maintaining, and protecting intellectual property rights, particularly for product candidates.
• Failure to realize anticipated benefits of the Kineta merger.
• Unexpected costs, charges, or expenses resulting from the Kineta merger.
• Unpredictability of cost, timing, scope, and results of clinical studies.
• Difficulty in retaining key professionals and hiring additional qualified professionals.
• Impact of existing regulations and regulatory developments, including lengthy, time-consuming, and inherently unpredictable FDA approval processes.
• Delays in obtaining required regulatory approvals for product candidates, which would materially impair the ability to generate revenue.
• Impact of government laws, general economic and market conditions, inflation, and imposition of new or revised global tariffs.
• Developments relating to competitors and the industry.
• Disruptions at the FDA and other government agencies (e.g., funding shortages, government shutdowns) could hinder product development, approval, or commercialization.
• Inability to raise additional funds or enter into collaborations/licensing arrangements when needed on favorable terms or at all, potentially forcing delays, reductions, or termination of product development or future commercialization efforts.
• Dilution of ownership interest for stockholders if additional capital is raised through the sale of equity or convertible debt securities.
• Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting the company's ability to take specific actions.
• Relinquishing valuable rights to product candidates, future revenue streams, or research programs if funds are raised through collaborations or similar arrangements with third parties.
• Inability to accurately predict the timing or amount of increased expenses or when or if profitability will be achieved or maintained.

Future Outlook

The company expects its existing capital resources, including anticipated remaining funds from the private placement and a bridge loan, to be sufficient to fund operations into the end of 2025. However, it anticipates operating losses will increase substantially as product candidates advance through development and regulatory approvals are sought. The company does not expect to generate product sales revenue until regulatory approval is obtained for one or more candidates, after which significant commercialization expenses are expected. Future capital requirements are dependent on clinical trial progress, regulatory outcomes, manufacturing costs, competition, and strategic partnerships, with no assurance that additional fundraising will be achieved on favorable terms.

Management Comments

• "The accompanying unaudited condensed consolidated financial statements are prepared in accordance with the instructions for Form 10-Q, and include all adjustments which we considered necessary for a fair presentation of the results for the periods presented."
• "The results for the three and nine months ended September 30, 2025 are not necessary indicative of the results to be expected for future periods or the full year."
• "We expect that our existing capital resources, including anticipated payment of the remaining funds from the Offering and bridge loan financing (Note 13) will be sufficient to fund the Companys planned future operations into the end of 2025."
• "However, there can be no assurance that any fundraising will be achieved or on commercially reasonable terms, if at all."
• "As such, there is substantial doubt about the Companys ability to continue as a going concern for the next 12 months from the date that these unaudited interim consolidated financial statements were available to be issued."
• "We anticipate these losses will increase substantially as it advances our product candidates through preclinical and clinical development, develops additional product candidates and seeks regulatory approvals for our product candidates."
• "We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtains regulatory approval for one or more product candidates."

Industry Context

TuHURA Biosciences operates in the highly competitive and capital-intensive immuno-oncology sector, focusing on overcoming resistance to cancer immunotherapies. The acquisition of Kineta and its VISTA-inhibiting monoclonal antibody (TBS-2025) aligns with a broader industry trend of targeting diverse immune checkpoints beyond traditional PD-1/L1 pathways. The initiation of a Phase 3 trial for IFx-2.0 in Merkel cell carcinoma, leveraging the FDA's accelerated approval pathway, reflects a common strategy in oncology to expedite market entry for therapies addressing unmet medical needs. The development of Delta Opioid Receptor technology for tumor microenvironment modulation (APCs and ADCs targeting MDSCs) indicates an industry-wide effort to develop multi-pronged approaches to enhance T cell function and overcome acquired resistance. The significant R&D expenses and ongoing need for capital are typical for clinical-stage biotech companies with multiple programs in development.

Comparison to Industry Standards

• The accumulated deficit of $134.4 million and consistent net losses are typical for clinical-stage biotechnology companies that are pre-revenue and heavily investing in research and development.
• The reliance on equity offerings, convertible notes, and bridge loans for funding is standard practice in the biotech industry, where product development is lengthy, expensive, and carries high risk.
• The use of the FDA's accelerated approval pathway for IFx-2.0 in Merkel cell carcinoma is a common strategy for therapies addressing serious conditions with unmet medical needs, potentially allowing earlier market access compared to traditional pathways, similar to approaches taken by companies like Merck with Keytruda in various oncology indications.
• The increase in R&D expenses by $5.1 million for the nine months ended September 30, 2025, reflects active clinical development, including the Phase 3 trial for IFx-2.0 and the integration of TBS-2025, which is consistent with a company advancing its pipeline, comparable to development stage expenditures seen in peers like smaller oncology-focused biotechs.
• The "going concern" warning is a common disclosure for pre-revenue biotech companies, indicating a need for continuous capital raises, but does not necessarily imply imminent failure if financing plans are in place. Many small biotechs operate with similar cash burn rates and rely on sequential funding rounds, such as those observed in early-stage companies like Kura Oncology or Mirati Therapeutics in their earlier development phases.

Corporate Governance

Legal Proceedings

• As of the date of this quarterly report, the company is not party to any material legal matters or claims.

Related Party Transactions

• On October 27, 2025, the company entered into a Secured Promissory Note and Loan Agreement for a bridge loan of up to $3,000,000 with an accredited investor and shareholder of the company (the Lender).
• On February 12, 2025, four holders (the Makers) of common stock purchase warrants, including KP Biotech Group, LLC, CA Patel F&F Investments, LLC, Dr. Kiran C. Patel, and Donald Wojnowski, issued secured promissory notes totaling $3,011,373 to the company as payment for warrant exercise.

Stakeholder Impact

• Shareholders face potential for significant dilution from future equity offerings (private placement, ATM offering) and warrant exercises, alongside high financial risk due to the 'going concern' warning.
• Employees, particularly those from the Kineta merger, are integrated into the company's operations, with key personnel retained or under consulting agreements.
• Creditors, including the bridge loan lender, face repayment risk given the company's 'going concern' warning and reliance on future financing.
• Future customers could benefit from the advancement of new immuno-oncology treatments, such as IFx-2.0 in Phase 3 and TBS-2025 in planned Phase 2 trials.
• Suppliers and partners involved in R&D and clinical trials will continue to be engaged as the company progresses its pipeline, subject to ongoing funding.

Next Steps

• Purchasers are obligated to fund the remaining $0.5 million of the Final Tranche Offering Amount by December 31, 2025.
• The company may loan up to an additional $1.5 million under the bridge loan agreement.
• The SEC needs to declare the Shelf Registration Statement for the $50 million ATM offering effective before shares can be sold.
• The company plans to investigate TBS-2025 in a randomized Phase 2 trial in combination with a menin inhibitor vs menin inhibitor alone in mutated NPM1 AML.
• Continue advancing product candidates through preclinical and clinical development and seek regulatory approvals.
• Finalize the determination of fair value for assets acquired and liabilities assumed in the Kineta acquisition by the end of 2025.
• Assess goodwill and IPR&D assets for impairment at least annually or whenever changes in circumstances indicate the carrying amount may not be recoverable.

Key Dates

Recommendation

The company faces substantial financial distress, evidenced by a rapidly depleting cash balance ($2.7 million as of Sep 30, 2025), significantly increased net losses, and an explicit 'going concern' warning. While strategic progress in clinical development (Phase 3 for IFx-2.0, Kineta acquisition) is noted, the immediate and pressing need for substantial additional funding, coupled with the inherent risks of clinical-stage biotech, creates a highly speculative and unfavorable investment profile. The potential for significant shareholder dilution from the announced $50 million ATM offering and other future capital raises further exacerbates the risk. A seasoned investor would likely view the current financial position as unsustainable without immediate and substantial external capital, making it a high-risk 'sell' given the uncertainty of successful financing on favorable terms.

Keywords

Immuno-oncology, Clinical stage, Cancer immunotherapies, IFx-2.0, Merkel cell carcinoma, Phase 3 trial, TBS-2025, VISTA inhibitor, Acute myeloid leukemia (AML), Kineta merger, SEC filing, 10-Q, Biotechnology, Drug development, Going concern, Capital raise, Private placement, ATM offering, Financial results, Net loss, Research and development, Corporate governance, Risk factors